4P-Pharma and Oncocross, a Korea-based AI biotech, signed a research collaboration agreement at the Institut Pasteur de Lille on October 25th, 2021. The two companies will join their expertise to bring an innovative therapeutic agent to the patients affected by Systemic Scleroderma, a rare autoimmune disease affecting the skin and internal organs that has no approved&hellip
Revital Rattenbach,4P-Pharma’s chairwoman is attending the 6th Drug Discovery summit on November 3rd, 2021, as a key speaker. She will give a talk on “Fast-Development of a CXCR4 antagonist to fight against Covid-19 pandemic.” For further information, please feel free to contact us by e-mail , or click here.
4P-Pharma is attending BIO-Europe! Join us at the digital event, October 25–28, 2021. Revital Rattenbach, our chairwoman, and Roselina Lam, our business development and licensing-in manager, participate to the event. To learn more about us and discuss future partnership, please feel free to connect with us via the partnering platform For further information, click here
It is our great pleasure to announce that 4Moving Biotech website is online! 4Moving Biotech is a French biotech start-up company, subsidiary of 4P-Pharma, dedicated to the clinical development of 4P004, a first-in-class disease-modifying drug for osteoarthritis. Click on the link and take a look! Exciting news will be announced!
4P-Pharma joins forces with Qingdao Marine Biomedical Research Institute for translation research in China and Europe
4P-Pharma and Qingdao Marine Biomedical Research Institute (QMBRI) have decided to combine their expertise to jointly develop their first-in-class drug candidates in China and Europe through the signature of a Memorandum of Understanding (MoU) to deal with their respective molecules. “[…] It is our ambition to create a fruitful and long-term partnership for our&hellip
Pr. Francis Berenbaum, 4Moving Biotech’s CEO and CMO, Head of Rheumatology department at Saint-Antoine Hospital (AP-HP), will present a poster entitled « Liraglutide Has Potent Anti-inflammatory And Anti-catabolic Activity In Two Cell Types Implicated In Osteoarthritis » (# POS0373) on our recent results on 4P004 during the European congress of rheumatology (EULAR) 2021 virtual congress that will take place on June 2-5, 2021. For further&hellip